US Patent 11066669 Oligonucleotides for modulating ATXN2 expression
All edits
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+561 characters)
Article
Patent abstract
The present invention relates to antisense oligonucleotides that are capable of modulating expression of ATXN2 in a target cell. The oligonucleotides hybridize to ATXN2 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of neurodegenerative diseases such as spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), Alzheimer's frontotemporal dementia (FTD), parkinsonism and conditions with TDP-43 proteinopathies using the oligonucleotide.
Edits on 10 Oct, 2023
Golden AI
Edits made to:
Infobox (+4 properties)
Infobox
Patent Inventor Names
Heidi Rye Hudlebusch0
Lykke Pedersen0
Peter Hagedorn0
Søren V. Rasmussen0
Edits on 20 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 24 Apr, 2023
Golden AI
Infobox
Patent Citations
Edits on 2 Apr, 2023
Golden AI
Infobox
Patent Citations
Edits on 25 Sep, 2022
Golden AI
Infobox
Is a
Patent Jurisdiction
Patent Number
110666690
Date of Patent
July 20, 2021
0Patent Application Number
164303390
Date Filed
June 3, 2019
0Official Website
Patent Citations
Patent Primary Examiner
Edits on 6 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 13 Feb, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 11066669 Oligonucleotides for modulating ATXN2 expression
Infobox
Is a
Patent jurisdiction
Patent number
11066669
Date of patent
July 20, 2021
Patent application number
16430339
Date Filed
June 3, 2019
Patent citations
Patent primary examiner
Find more entities like US Patent 11066669 Oligonucleotides for modulating ATXN2 expression
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
